ABOUT

The aim of Clarus Analytical is to provide clear, accurate, and precise analytical data to clients in both academic and Pharma/Biotech sectors. The company was founded by Dr. Ilya Gertsman, PhD.  Dr. Gertsman received his doctorate in structural biology and protein biochemistry,  extensively using mass spectrometry for his studies. He then went on to work for over 10 years in the University of California-San Diego Biochemical Genetics Laboratory (BGL), a CLIA/CAP accredited clinical laboratory, eventually rising to the ranks of Assistant Professor before departing to start his own company.  In the BGL laboratory,  Dr Gertsman became an expert in LC-MS method development and also gained proficiency in clinical assay development. He primarily used metabolomics to investigate inborn errors of metabolism and other forms of metabolic disease, in addition to also leading a Core service for biomarker discovery.  Clarus specializes in LC-MS based technologies for both rigourous quantification (LC-triple-quadrupole MS) and biomarker/untargeted analysis (LC-QTOF MS).

Selected publications

  • Gertsman I,  Wuu J,. McAlnois-Downes M, Ghassemian M, Ling K, Rigo F, Bennett F, Miller TM, Da Cruz S.  An endogenous peptide marker differentiates SOD1 stability and facilitates pharmacodynamic monitoring in SOD1 amyotrophic lateral scleorsis. JCI Insight.  4:10 (2019)

  • Gertsman I, Gangoiti JA, Barshop BA. Validation of a dual LC–HRMS platform for clinical metabolic diagnosis in serum, bridging quantitative analysis and untargeted metabolomics. Metabolomics 10 312-23 (2014).

  • Gertsman I, Gangoiti JA, Nyhan WL, Barshop BA.  Perturbations of tyrosine metabolism promote the indolepyruvate pathway via tryptophan in host and microbiome.  Molecular Genetics and Metabolism 114, 431-437 (2015)

  • Gertsman, I. Barshop, BA. Promises and pitfalls of untargeted metabolomics. Journal of Inherited and Metabolic Disease 41(3):355-366 (2018)

  • Gertsman I, Johnson, WS, Nishikawa CM, Gangoiti JA, Holmes B, Barshop BA. Diagnosis and monitoring of cystinosis using immunomagnetically purified granulocytes. Clinical Chemistry 62, 766-772 (2016).

  • Gertsman I, Panyard-Davis J, Golden G, Gangoiti JA, Nyhan WL, Barshop BA.  Metabolic effects of increasing doses of nitisinone in the treatment of alkaptonuria. JIMD Reports 24, 13-20 (2015).

  • Rocca CJ, Goodman SM, Dulin JN, Haquang JH, Gertsman I, Blondelle J, Smith JLM, Heyser CJ, Cherqui S. Transplantation of wild-type mouse hematopoietic stem and progenitor cells ameliorates deficits in a mouse model of Friedreich's ataxia. Science Translational Medicine. 2017 Oct 25;9(413).

  • Gertsman I, Gan L, Guttman M, Lee KK, Duda RL, Hendrix R, Komives EA, Johnson JE. An Unexpected Twist in Virus maturation. Nature 458, 646-50 (2009).

Collaborators and advisors
Bruce A. Barshop MD, Ph.D

Professor, director of UCSD Biochemical Genetics Laboratory.  Specializes in diagnosis and treatment of inborn errors of metabolism

 

Majid Ghassemian PhD
Jon A Gangoiti
MS
Nathan Hanan
Pharm.D.

Director of Biomolecular mass spec facility/proteomcs core at UCSD. Specializes in protein quantitation and identification, as well as the characterization of post-translational modifications

 

Lead chemist, Biochemical Genetics Laboratory, UCSD.  Specializing in MS-based method development and validation

Clinical Pharmacologist. Specializes in pharmacometrics, including data population PK/PD modeling and simulation.

Copyright @2020 Clarus Analytical LLC. All rights reserved